Terms ending in 2039
Every in-force patent on Allergan, Inc.'s record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,890,457 | Aspiration and Injection Device In force · High confidence | Allergan, Inc. | In force | High confidence | |
| US 10,610,518 | Presbyopia Treatments In force · High confidence | Allergan, Inc. | In force | High confidence | |
| US 11,285,134 | Presbyopia Treatments In force · High confidence | Allergan, Inc. | In force | High confidence | |
| US 11,096,958 | Sodium Chlorite Compositions with Enhanced Anti-Microbial Efficacy and Reduced Toxicity In force · High confidence | Allergan, Inc. | In force | High confidence | |
| US 11,738,043 | Sodium Chlorite Compositions with Enhanced Anti-Microbial Efficacy and Reduced Toxicity In force · High confidence | Allergan, Inc. | In force | High confidence | |
| US 12,527,816 | Sodium Chlorite Compositions with Enhanced Anti-Microbial Efficacy and Reduced Toxicity In force · Medium confidence | Allergan, Inc. | In force | Medium confidence | |
| US D1,027,647 | Bottle Holder In force · High confidence | Allergan, Inc. | In force | High confidence | |
| US 12,383,545 | Treatment of Migraine In force · High confidence | Allergan Pharmaceuticals International Limited | In force | High confidence | |
| US 10,787,447 | Pharmaceutical Compounds In force · High confidence | Nxera Pharma UK Limited | In force | High confidence | |
| US 10,858,352 | Pharmaceutical Compounds In force · High confidence | Nxera Pharma UK Limited | In force | High confidence | |
| 4 more term ends in 2039 · Pro | |||||
10 of 14 patents shown. Soonest term end first, then patent number.
Pro members see all 14.
10 of these are in force and held by Allergan, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.